Last updated on November 2018

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102 an Immune-priming GM-CSF Coding Oncolytic Adenovirus and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma


Brief description of study

The trial is an open-label, parallel group, multicentre trial that will recruit a total of 30 patients with malignant pleural mesothelioma. The trial will be conducted in 2 phases: a non-randomised safety phase and a randomised phase. The safety phase will consist of a lead-in cohort of 6 patients treated with ONCOS 102 and pemetrexed/cisplatin. The randomised phase will not commence until the DSMB has deemed the safety lead-in data appropriate for continuation. A total of 24 patients will be included in the randomised phase; 14 patients will be randomised to receive ONCOS 102 and pemetrexed/cisplatin, and 10 patients will receive pemetrexed/cisplatin alone. The trial's main objectives are determination of safety, immune activation, clinical response and the correlation between clinical outcome and the immunological data.

Clinical Study Identifier: NCT02879669

Contact Investigators or Research Sites near you

Start Over

Santiago Viteri

Hospital Universitario Quir n
Barcelona, Spain
  Connect »

Joaquim Bosch

Hospital Universitari de Girona Doctor Josep Trueta - Institut Catal d'Oncologia
Girona, Spain
  Connect »

Luis Paz-Ares, MD

Hospital 12 de octubre
Madrid, Spain
  Connect »

Javier de Castro, MD

Hospital Universitario HM Sanchinarro
Madrid, Spain
  Connect »

Nicolas Isambert, MD

Centre Georges-Fran ois Leclerc
Dijon, France
  Connect »

Hervé Lena, MD

CHU de Rennes - Pontchaillou
Rennes, France
  Connect »

Susanna Cedres, MD

Vall d'Hebron Univerity Hospital
Barcelona, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.